Silicon Labs posts Q3 profit and suspends guidance amid pending Texas Instruments acquisition

Silicon Labs reported third‑quarter 2026 revenue of $251 million, up 22% year‑over‑year, and GAAP net income of $8.9 million, generating GAAP EPS of $0.26. Non‑GAAP EPS was $1.05, reflecting a 228% increase from the prior year. Medical sales set a quarterly record, rising 48% sequentially and more than 300% year‑over‑year. The company suspended forward‑looking guidance because its pending cash acquisition by Texas Instruments is expected to close in the first half of 2027.

The suspension of guidance leaves investors without near‑term forecasts, increasing reliance on the pending merger terms for valuation (the company disclosed the acquisition in its release). Susquehanna reiterated a neutral rating, noting the stock’s outlook is tied to the Texas Instruments deal.

  • 1Revenue was $251 million, up 22% year‑over‑year.
  • 2GAAP diluted earnings per share was $0.26.
  • 3Non‑GAAP diluted earnings per share was $1.05.
  • 4Medical revenue increased 48% sequentially and more than 300% year‑over‑year.
  • 5Silicon Labs suspended forward‑looking guidance due to the pending acquisition by Texas Instruments.
  • 6GAAP net income was $8.9 million.

Sources